Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.52 |
| ▸ | CA1 | P00915 | 7/20 | 0.52 |
| ▸ | CA9 | Q16790 | 6/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 2/20 | 0.47 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22071071 | 0.93 | CA2 (0.49) | CA2CA1CA9TSHRCA5A | |
| SCHEMBL1621831 | 0.89 | CA2 (0.55) | CA2CA1CA9TSHRCA5A | |
| SCHEMBL23461748 | 0.86 | CA2 (0.52) | CA2CA1CA9TSHRCA5A | |
| SCHEMBL6859545 | 0.85 | TSHR (0.52) | CA2CA1CA9TSHRTDP1 | |
| SCHEMBL7195587 | 0.82 | TSHR (0.48) | CA2CA1CA9TSHRCA7 | |
| SCHEMBL2086018 | 0.82 | TSHR (0.48) | CA2CA1CA9TSHRTDP1 | |
| SCHEMBL29990163 | 0.82 | TSHR (0.48) | CA2CA1CA9TSHRTDP1 | |
| SCHEMBL16782126 | 0.81 | TSHR (0.47) | CA2CA1CA9TSHRTDP1 | |
| SCHEMBL16782117 | 0.81 | TSHR (0.47) | CA2CA1CA9TSHRTDP1 | |
| SCHEMBL16782118 | 0.81 | TSHR (0.47) | CA2CA1CA9TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1833821-B1 | SULFAMIDES AS ENDOTHELIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-03-30 | — | — | EP | disclosed |
| US-7868012-B2 | Sulfamides as endothelin receptor antagonists for the treatment of cardiovascular diseases | ACTELION PHARMACEUTICALS, LTD. (CH) | 2011-01-11 | — | — | US | disclosed |
| US-20080004298-A1 | Sulfamides as Endothelin Receptor Antagonists for the Treatment of Cardiovascular Diseases | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-01-03 | — | — | US | disclosed |
| EP-1833821-A2 | SULFAMIDES AS ENDOTHELIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | Actelion Pharmaceuticals Ltd. (CH) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006051502-A2 | SULFAMIDES AS ENDOTHELIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004298-A1 | Sulfamides as Endothelin Receptor Antagonists for the Treatment of Cardiovascular Diseases | EDNRA, EDNRB, ECE1 | CA2 980/4885CA1 3941/4885CA9 2546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.